Steven Dunn

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


9 publications

2023 | 2022 | 2021 | 2020 | 2019 | 2014 |
2023
From bench to bedside: 64Cu/177Lu 1C1m-Fc anti TEM-1: mice-to-human dosimetry extrapolations for future theranostic applications.
Gnesin S., Chouin N., Cherel M., Dunn S.M., Schaefer N., Faivre-Chauvet A., Prior J.O., Delage J.A., 2023/06/14. EJNMMI research, 13 (1) p. 59. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_91574209E2BB]
2022
A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors.
Fierle J.K., Abram-Saliba J., Atsaves V., Brioschi M., de Tiani M., Reichenbach P., Irving M., Coukos G., Dunn S.M., 2022/01/21. Scientific reports, 12 (1) p. 1136. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7D41964E1822]
2021
Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety.
Delage J.A., Gnesin S., Prior J.O., Barbet J., Le Saëc P., Marionneau-Lambot S., Gouard S., Chérel M., Bourgeois M., Schaefer N. et al., 2021/11/25. Cancers, 13 (23) p. 5936. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1AE49D79BF32]
Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1.
Fierle J.K., Brioschi M., de Tiani M., Wetterwald L., Atsaves V., Abram-Saliba J., Petrova T.V., Coukos G., Dunn S.M., 2021/08/17. Cell reports. Medicine, 2 (8) p. 100362. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3930B2D62A38]
Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [177Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model.
Delage J.A., Faivre-Chauvet A., Barbet J., Fierle J.K., Schaefer N., Coukos G., Viertl D., Dunn S.M., Gnesin S., Prior J.O., 2021/01/13. Pharmaceutics, 13 (1) p. 96. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_28C0A40301A0]
 
Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies.
D'Onofrio A., Gano L., Melo R., Mendes F., Oliveira M.C., Denoël T., Schaefer N., Viertl D., Fierle J., Coukos G. et al., 2021/01. European journal of pharmaceutics and biopharmaceutics, 158 pp. 233-244. Peer-reviewed.
[DOI][Pmid][serval:BIB_95FD98ADDB6D]
2020
 
177Lu radiolabeling and preclinical theranostic study of 1C1m-Fc: an anti-TEM-1 scFv-Fc fusion protein in soft tissue sarcoma
Delage J.A., Faivre-Chauvet A., Fierle J.K., Gnesin S., Schaefer N., Coukos G., Dunn S.M., Viertl D., Prior J.O., 2020/08/17. EJNMMI research, 10 (1) p. 98. Peer-reviewed.
[DOI][Pmid][serval:BIB_4E04534CDA56]
2019
Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery.
Fierle J.K., Abram-Saliba J., Brioschi M., deTiani M., Coukos G., Dunn S.M., 2019/09/06. Scientific reports, 9 (1) p. 12815. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FCB67A02E15F]
2014
Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer.
Li C., Wang J., Hu J., Feng Y., Hasegawa K., Peng X., Duan X., Zhao A., Mikitsh J.L., Muzykantov V.R. et al., 2014. Oncotarget, 5 (16) pp. 6994-7012.
[URN][WoS][Pmid][serval:BIB_64D8F7C9B69C]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University